FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W66321831> ?p ?o ?g. }

• W66321831 endingPage "6188" @default.
• W66321831 startingPage "6188" @default.
• W66321831 abstract "Before pegylated interferon alpha (IFN) was introduced for the therapy of chronic hepatitis C virus (HCV)-induced hepatitis, conventional thrice weekly IFN therapy was supplemented by ribavirin. Also, at that time, higher and more frequent doses of IFN were expected to be more effective than the standard regimen of 3 MU thrice weekly. As ribavirin significantly increases side effects and negatively influences the quality of life particularly in young patients, we started a prospective non-randomized study with a daily IFN-2a monotherapy as an initial treatment for chronic hepatitis C.Forty-six consecutive chronic HCV-infected patients received 3 MU IFN-2a per day as an initial treatment. Patients with genotype 2 or 3 (n = 12) were treated for 24 wk, and patients with genotypes other than 2 or 3 (n = 34) for 48 wk. Treatment outcome was followed up for 48 wk after the end of treatment (EOT). Virological response was defined as the absence of detectable serum HCV-RNA. Patients without virological response at 12 wk after the start of treatment received low-dose ribavirin (10 mg(kg/d)) additionally.During treatment, three genotype 3 patients were excluded from the study due to incompliance. The remaining patients (n = 9) infected with genotype 2 or 3 showed an initial virological response rate of 100%. Six patients (66.7%) were still found to be virus-free at the end of follow-up period. In these patients, initial virological response was evident already after 2 wk of treatment. In contrast, initial virological response occurred first after 4 wk of treatment in the three patients who relapsed (33.3%). In comparison, patients infected with genotypes other than 2 or 3 (n = 34) showed an initial virological response rate of only 23.5% (n = 8), and even in combination with ribavirin a sustained virological response (SVR) rate of only 11.8% (n = 4) could be achieved.In chronic HCV-infected patients with genotype 2 or 3, a SVR can be expected after 24 wk of daily dose IFN-2a treatment without ribavirin, if initial virological response develops early. This finding is worth to be confirmed in a prospective randomized study with pegylated IFN." @default.
• W66321831 created "2016-06-24" @default.
• W66321831 creator A5014751782 @default.
• W66321831 creator A5023994396 @default.
• W66321831 creator A5055539335 @default.
• W66321831 creator A5060478090 @default.
• W66321831 creator A5064466782 @default.
• W66321831 date "2005-01-01" @default.
• W66321831 modified "2023-09-23" @default.
• W66321831 title "Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients" @default.
• W66321831 cites W1966049263 @default.
• W66321831 cites W1974249420 @default.
• W66321831 cites W1981095040 @default.
• W66321831 cites W1985882441 @default.
• W66321831 cites W1995403987 @default.
• W66321831 cites W2006309458 @default.
• W66321831 cites W2015336471 @default.
• W66321831 cites W2027545702 @default.
• W66321831 cites W2043519223 @default.
• W66321831 cites W2047329659 @default.
• W66321831 cites W2065306302 @default.
• W66321831 cites W2069633422 @default.
• W66321831 cites W2073566049 @default.
• W66321831 cites W2079771726 @default.
• W66321831 cites W2112876622 @default.
• W66321831 cites W2127685726 @default.
• W66321831 cites W2129767605 @default.
• W66321831 cites W2165715544 @default.
• W66321831 cites W2182064632 @default.
• W66321831 cites W2317554121 @default.
• W66321831 cites W2324539587 @default.
• W66321831 cites W2332630894 @default.
• W66321831 cites W2408841051 @default.
• W66321831 cites W2438653439 @default.
• W66321831 cites W2464243271 @default.
• W66321831 cites W2893056655 @default.
• W66321831 doi "https://doi.org/10.3748/wjg.v11.i39.6188" @default.
• W66321831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4436638" @default.
• W66321831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16273648" @default.
• W66321831 hasPublicationYear "2005" @default.
• W66321831 type Work @default.
• W66321831 sameAs 66321831 @default.
• W66321831 citedByCount "3" @default.
• W66321831 crossrefType "journal-article" @default.
• W66321831 hasAuthorship W66321831A5014751782 @default.
• W66321831 hasAuthorship W66321831A5023994396 @default.
• W66321831 hasAuthorship W66321831A5055539335 @default.
• W66321831 hasAuthorship W66321831A5060478090 @default.
• W66321831 hasAuthorship W66321831A5064466782 @default.
• W66321831 hasBestOaLocation W663218311 @default.
• W66321831 hasConcept C104317684 @default.
• W66321831 hasConcept C126322002 @default.
• W66321831 hasConcept C135763542 @default.
• W66321831 hasConcept C203014093 @default.
• W66321831 hasConcept C2522874641 @default.
• W66321831 hasConcept C2776178377 @default.
• W66321831 hasConcept C2776408679 @default.
• W66321831 hasConcept C2776455275 @default.
• W66321831 hasConcept C2776461080 @default.
• W66321831 hasConcept C2780040827 @default.
• W66321831 hasConcept C2781228144 @default.
• W66321831 hasConcept C2781413609 @default.
• W66321831 hasConcept C2781463415 @default.
• W66321831 hasConcept C2909179924 @default.
• W66321831 hasConcept C55493867 @default.
• W66321831 hasConcept C71924100 @default.
• W66321831 hasConcept C86803240 @default.
• W66321831 hasConcept C90924648 @default.
• W66321831 hasConceptScore W66321831C104317684 @default.
• W66321831 hasConceptScore W66321831C126322002 @default.
• W66321831 hasConceptScore W66321831C135763542 @default.
• W66321831 hasConceptScore W66321831C203014093 @default.
• W66321831 hasConceptScore W66321831C2522874641 @default.
• W66321831 hasConceptScore W66321831C2776178377 @default.
• W66321831 hasConceptScore W66321831C2776408679 @default.
• W66321831 hasConceptScore W66321831C2776455275 @default.
• W66321831 hasConceptScore W66321831C2776461080 @default.
• W66321831 hasConceptScore W66321831C2780040827 @default.
• W66321831 hasConceptScore W66321831C2781228144 @default.
• W66321831 hasConceptScore W66321831C2781413609 @default.
• W66321831 hasConceptScore W66321831C2781463415 @default.
• W66321831 hasConceptScore W66321831C2909179924 @default.
• W66321831 hasConceptScore W66321831C55493867 @default.
• W66321831 hasConceptScore W66321831C71924100 @default.
• W66321831 hasConceptScore W66321831C86803240 @default.
• W66321831 hasConceptScore W66321831C90924648 @default.
• W66321831 hasIssue "39" @default.
• W66321831 hasLocation W663218311 @default.
• W66321831 hasLocation W663218312 @default.
• W66321831 hasLocation W663218313 @default.
• W66321831 hasLocation W663218314 @default.
• W66321831 hasOpenAccess W66321831 @default.
• W66321831 hasPrimaryLocation W663218311 @default.
• W66321831 hasRelatedWork W118298973 @default.
• W66321831 hasRelatedWork W1911438026 @default.
• W66321831 hasRelatedWork W1984480354 @default.
• W66321831 hasRelatedWork W2007857109 @default.
• W66321831 hasRelatedWork W2018887507 @default.

• next